| 4.61 -0.02 (-0.43%) | 07-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.99 | 1-year : | 7 |
| Resists | First : | 5.13 | Second : | 5.99 |
| Pivot price | 3.84 |
|||
| Supports | First : | 3.35 | Second : | 2.25 |
| MAs | MA(5) : | 4.54  |
MA(20) : | 3.5 |
| MA(100) : | 2.79 |
MA(250) : | 3.72 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 77.7 |
| RSI | RSI(14): 72 |
|||
| 52-week | High : | 7.13 | Low : | 2.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GALT ] has closed below upper band by 28.5%. Bollinger Bands are 332.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.66 - 4.69 | 4.69 - 4.72 |
| Low: | 4.25 - 4.28 | 4.28 - 4.3 |
| Close: | 4.57 - 4.61 | 4.61 - 4.66 |
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Mon, 06 Jul 2026
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Tue, 30 Jun 2026
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Tue, 30 Jun 2026
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Mon, 29 Jun 2026
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Sun, 28 Jun 2026
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
Fri, 26 Jun 2026
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 29 (%) |
| Held by Institutions | 21.1 (%) |
| Shares Short | 7,870 (K) |
| Shares Short P.Month | 7,360 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -80.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -11.25 |
| PEG Ratio | -36.2 |
| Price to Book value | -2.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|